BioCentury
ARTICLE | Politics & Policy

China lists 30 more overseas drugs eligible for Priority Review

March 28, 2019 9:38 PM UTC

China’s Drug Evaluation Center posted a second batch of drugs already approved in the U.S., EU or Japan that could be eligible for Priority Review in China.

Fourteen of the 30 drugs on the list target rare diseases. Other drugs were included because they address public health needs, have obvious clinical advantages, treat pediatric diseases or target diseases lacking effective therapies...